Mission and business strategy

The core competence of the Aenova Group lies in developing and manufacturing solid, semi-solid and liquid dosage forms, offering its customers a full service portfolio, ranging from development, the purchase of raw materials, production and analysis through to packaging and logistics. Both acquisitions of Euro Vital Pharma and the Temmler Group gave a strong competitive advantage, extending Aenova’s portfolio. Focus at Euro Vital Pharma is on the development, manufacture and marketing of health products for private label and brand customers. As a result, Aenova’s portfolio of licenced products will include around 60 additional salves, gels, syrups and lotions. Takeover of the Temmler Group became effective in December 2012 enlarging its offering of technologies with semi-solid and liquid dosage forms such as salves, gels and drops. Temmler’s six production sites, with around 1,000 employees, will be fully integrated into the Aenova group of companies during the course of 2013. One of Temmler’s site in, with 140 employees, is located in Carugate near Milan, giving the Aenova Group a strong local presence in Italy. «Aenova – says Heiner Hoppmann – has strong Corporate Values: to be dynamic and success-oriented; customer-oriented and sustainable; fair and reliable; responsible and strong; transparent and open. Our goal is the leadership, intended not only as a volume but as a quality leadership. Our mission to be the business to business partner of choice worldwide for the pharmaceutical and healthcare industry, relying on high quality standards and innovative technologies. Our business strategy to expand strategic CDMO accounts, to exploit private label market leadership, to continue expansion into new and emerging OTC/VMS markets and further to develop our outlicensing business on own products.